XML 44 R31.htm IDEA: XBRL DOCUMENT v3.21.2
Organization and Summary of Significant Accounting Policies - Additional Information (Detail)
 1 Months Ended 3 Months Ended 9 Months Ended
May 31, 2021
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Segment
Sep. 30, 2020
USD ($)
Dec. 31, 2020
USD ($)
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Number of operating segment | Segment       1    
Cash, cash equivalents and marketable securities   $ 414,200,000   $ 414,200,000    
Long-term debt, net of debt discount           $ 1,094,000
Debt maturity date       May 15, 2026    
Net (loss) income   (28,430,000) $ 4,401,000 $ (23,066,000) $ (59,773,000)  
Inventory reserve   0 $ 0 $ 0 $ 0  
Maximum            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Expected period of payment to be received       1 year    
2.50% Convertible Senior Notes Due 2026            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Aggregate principal amount $ 225,500,000 225,500,000   $ 225,500,000    
Debt interest rate 2.50%          
Long-term debt, net of debt discount   $ 5,300,000   $ 5,300,000    
Debt maturity date       May 15, 2026    
Loan Agreement            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Repayments of debt $ 190,200,000     $ 190,200,000    
Capped Calls            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Net Proceeds to Pay the Costs $ 27,200,000     $ 27,200,000    
HEPLISAV-B            
Organization Consolidation And Presentation Of Financial Statements Disclosure [Line Items]            
Minimum age approved for vaccine prevention of infection caused       18 years